Inclusion Criteria:

- Diagnosis of RA as defined by the American College of Rheumatology (ACR) and
consistent with revised criteria for RA

- Stable disease-modifying drug regimen for 3 months prior to study entry, with no
change in drug dosage for at least 3 months prior to study entry

- Relatively stable disease course for 3 months prior to study entry

- If treated with corticosteroids, must be on a stable dosage for 3 months prior to
study entry

- If taking prednisone, must be on a dosage less than or equal to 10 mg/day or
equivalent

- Resides in Greater Los Angeles area

Exclusion Criteria:

- Inactive RA conditions defined as "in remission"

- Experiencing frequent, severe disease flares that require changes in primary
disease-modifying regimen

- Serious medical conditions, including: diabetes, congestive heart failure, renal
failure requiring specific treatment, cancer (unless cured for period of 5 years or
more), unregulated endocrine disorders (including thyroid disorders), chronic
uncontrolled infection, or any uncontrolled medical condition that may interfere with
the study

- Use of analgesics (e.g., opioids) other than acetaminophen or non-steroidal
anti-inflammatory agents prescribed for RA treatment, tramadol (Ultram) or Tylenol
with codeine on an as-needed basis, or propoxyphen (Darvocet, Wygesic)

- Use of oxycodone (Percocet), hydrocodone (Vicodin), morphine, or hydromorphone
(Dilaudid)

- Use of high levels of methotrexate (greater than 7.5 mg)

- Use of nitrogen mustard, cyclosporine, monoclonal antibodies, or cyclophosphamide
within the 6 months prior to study entry

- Serious psychiatric conditions, such as bipolar disorder, psychotic disorders, or
organic brain syndromes

- At risk for suicide

- Dependent on canes, walkers, or other assistive devices

- Unable to commit to study schedule/itinerary or unwilling to be assigned to any of
the 3 treatment groups